• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    5/9/25 7:05:06 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    8-K
    false 0001815442 0001815442 2025-05-09 2025-05-09
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 9, 2025

     

     

    KYMERA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39460   81-2992166
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)

    Kymera Therapeutics, Inc.

    500 North Beacon Street, 4th Floor
    Watertown, Massachusetts 02472
    (Address of principal executive offices, including zip code)

    (857) 285-5300

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trade

    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.0001 par value per share   KYMR   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02.

    Results of Operations and Financial Condition

    On May 9, 2025, Kymera Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

    The information in this contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 7.01.

    Regulation FD Disclosure

    On May 9, 2025, the Company issued a press release announcing its new oral degrader product candidate, KT-579, an IRF5 degrader, a copy of which is furnished herewith as Exhibit 99.2.

    The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01.

    Exhibits

    (d) Exhibits

     

    Exhibit
    No.
       Description
    99.1    Press release issued by Kymera Therapeutics, Inc. on May 9, 2025 furnished herewith.
    99.2    Press release issued by Kymera Therapeutics, Inc. on May 9, 2025, furnished herewith.
    104    Cover Page Interactive Data


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Kymera Therapeutics, Inc.
    Date: May 9, 2025     By:  

    /s/ Nello Mainolfi

          Nello Mainolfi, Ph.D.
          President and Chief Executive Officer
    Get the next $KYMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    12/6/2024$55.00Market Perform
    BMO Capital Markets
    12/2/2024$57.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$65.00Overweight
    Stephens
    9/9/2024$60.00Outperform
    Leerink Partners
    8/26/2024$65.00Peer Perform → Outperform
    Wolfe Research
    4/22/2024$53.00Outperform
    Oppenheimer
    More analyst ratings

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

      WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference in Las Vegas, NV on May 14, 2025, at 3:40 p.m. PT. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.  About Kymera TherapeuticsKymera is a clinical-stage biotechnology company

      5/7/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kymera Therapeutics with a new price target

      Citigroup initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $52.00

      3/13/25 8:12:58 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Kymera Therapeutics with a new price target

      BTIG Research initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00

      12/10/24 8:28:42 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Kymera Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Kymera Therapeutics with a rating of Market Perform and set a new price target of $55.00

      12/6/24 7:53:24 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kymera Therapeutics Inc.

      10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)

      5/9/25 7:15:41 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

      5/9/25 7:05:06 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.

      SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      4/30/25 11:12:25 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 4:31:20 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 1:22:39 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 9:30:22 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      8/22/24 4:03:26 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bvf Partners L P/Il bought $5,301,325 worth of shares (414,105 units at $12.80) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      11/6/23 6:07:28 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Goodman Noah was granted 50,000 shares, increasing direct ownership by 61,396% to 50,081 units (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/9/25 8:05:05 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Goodman Noah claimed ownership of 81 shares (SEC Form 3)

      3 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/9/25 8:00:05 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Jacobs Bruce N. exercised 25,000 shares at a strike of $2.08, increasing direct ownership by 12% to 226,886 units (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      4/1/25 8:00:03 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

      Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline. To join the video call or view the li

      4/24/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

      WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company. "We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity," said Nello Mainolfi, Ph.D., Founder,

      4/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Financials

    Live finance-specific insights

    See more
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively KT-295 (TYK2) Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25 KT-474/SAR444656 (IRAK4) Phase 2b trials in hidradenitis suppurativa (HS) and AD ongoing, led by partner Sanofi, with primary completion of both trials expected by mid-2026 New oral degrader program against a high-value immunology target to be announced in early May 2025 in a company webcast Well-capitali

      2/27/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

      WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Ky

      2/20/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care